Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma

Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma
ShareXFacebook

(MedPage Today) -- CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to the SARC041 trial. Patients...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement